Molecular structure of Ridaforolimus, CAS Number: 572924-54-0
Ridaforolimus (CAS 572924-54-0)
See product citations (1)
Alternate Names:
Rapamycin 42-(Dimethylphosphinate)
Application:
Ridaforolimus is a selective mTOR (FRAP) inhibitor
CAS Number:
572924-54-0
Purity:
≥99%
Molecular Weight:
990.21
Molecular Formula:
C53H84NO14P
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ridaforolimus is a compound that is of significant interest in the field of cancer research, where it is studied for its role as a selective inhibitor of the mammalian target of rapamycin (mTOR). This intracellular kinase is a critical regulator of cell growth, proliferation, and survival, and its dysregulation is implicated in the pathogenesis of various cancers. Research on ridaforolimus involves investigating its impact on signaling pathways related to mTOR, with the goal of understanding how inhibition can affect tumor growth and survival. By examining the effects of ridaforolimus on cellular processes such as protein synthesis and autophagy, researchers aim to elucidate the mechanisms by which mTOR contributes to oncogenesis and tumor maintenance.
Ridaforolimus (CAS 572924-54-0) References
- Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. | Rivera, VM., et al. 2011. Mol Cancer Ther. 10: 1059-71. PMID: 21482695
- Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity? | Garrido-Laguna, I. and Janku, F. 2012. J Clin Oncol. 30: 892-3. PMID: 22291080
- Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. | Squillace, RM., et al. 2012. Int J Oncol. 41: 425-32. PMID: 22614157
- Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. | Gozgit, JM., et al. 2013. Cancer Chemother Pharmacol. 71: 1315-23. PMID: 23468082
- Pharmacokinetic Evaluation of a DSPE-PEG2000 Micellar Formulation of Ridaforolimus in Rat. | Remsberg, CM., et al. 2012. Pharmaceutics. 5: 81-93. PMID: 24300398
- Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells. | Morgan, SS. and Cranmer, LD. 2014. BMC Res Notes. 7: 812. PMID: 25406429
- Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. | Becker, MA., et al. 2016. BMC Cancer. 16: 814. PMID: 27765027
- Structural Aspects of mTOR Inhibitors: Search for Potential Compounds. | Kaur, K., et al. 2022. Anticancer Agents Med Chem. 22: 1037-1055. PMID: 34288843
- TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. | Agarwal, N., et al. 2021. Proc Natl Acad Sci U S A. 118: PMID: 34518220
- Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (Cryptotis parva). | Belkacemi, L., et al. 2022. Front Pharmacol. 13: 848673. PMID: 35444553
- Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. | Shi, G., et al. 2022. J Clin Invest. 132: PMID: 36264642
- Why is rapamycin not a rapalog? | Hodzic Kuerec, A. and Maier, AB. 2023. Gerontology.. PMID: 36617414
- Cellular senescence: when growth stimulation meets cell cycle arrest. | Blagosklonny, MV. 2023. Aging (Albany NY). 15: 905-913. PMID: 36805938
- Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding. | Islam, MK., et al. 2023. Sci Rep. 13: 3643. PMID: 36871056
Inhibitor of:
mTOR, NICE-1, NPRL2, PL6, Raptor, REDD-2, TBC1D7, and Tor2.Activator of:
hamartin, HSP 56, and NPRL3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ridaforolimus, 5 mg | sc-212783 | 5 mg | $248.00 |